We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Scientists from the Israeli Institute for Biological Research (IIBR) claim that analogues of two drugs used for the treatment of Gaucher’s disease could be effective against Covid-19.
Sanofi Genzyme, a division of Sanofi-Aventis Canada Inc., announced Health Canada has approved Cerdelga (eliglustat capsules) for the treatment of adult patients with Gaucher Disease Type 1.